At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 34 enrolled
Drug / intervention
Ixazomib +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2, Open-Label, Multicenter Study of Ixazomib Plus Lenalidomide and Dexamethasone in Adult Japanese Patients With Relapsed and/or Refractory Multiple Myeloma
In Brief
A Phase 2 clinical trial evaluating Ixazomib, Lenalidomide, and 1 other intervention for Relapsed and/or Refractory Multiple Myeloma. Completed, enrolled 34 participants across 21 sites.
Detailed Summary
The purpose of this study is to evaluate the efficacy and safety of ixazomib plus lenalidomide and dexamethasone in Japanese participants with relapsed and/or refractory multiple myeloma (RRMM).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesJapan
Collaborators--
Timeline
Phase 2CompletedFinished
2017201820192020202120222023202420252026
First PostedSep 2016
Enrollment StartNov 2016
Primary CompletionAug 2019
TodayJul 2026
First PostedSep 28, 2016
Enrollment StartNov 1, 2016
Primary CompletionAug 31, 2019
TodayJul 2, 2026
Enrollment to primary: 2.8 yearsPosted 9.8 years ago
Interventions
Ixazomibdrug
Ixazomib capsules
Lenalidomidedrug
Lenalidomide capsules
Dexamethasonedrug
Dexamethasone Tablets